217 related articles for article (PubMed ID: 33662683)
21. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
22. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
23. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
[TBL] [Abstract][Full Text] [Related]
24. In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations.
Qayed WS; Ferreira RS; Silva JRA
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144718
[TBL] [Abstract][Full Text] [Related]
25. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
Sivakumar D; Stein M
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
[TBL] [Abstract][Full Text] [Related]
26. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
27. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
28. Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Ribaudo G; Yun X; Ongaro A; Oselladore E; Ng JPL; Haynes RK; Law BYK; Memo M; Wong VKW; Coghi P; Gianoncelli A
Chem Biol Drug Des; 2023 Apr; 101(4):809-818. PubMed ID: 36453012
[TBL] [Abstract][Full Text] [Related]
29. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.
Chourasia M; Koppula PR; Battu A; Ouseph MM; Singh AK
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668085
[TBL] [Abstract][Full Text] [Related]
30. Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro.
Lewis DSM; Ho J; Wills S; Kawall A; Sharma A; Chavada K; Ebert MCCJC; Evoli S; Singh A; Rayalam S; Mody V; Taval S
Sci Rep; 2022 Feb; 12(1):2145. PubMed ID: 35140265
[TBL] [Abstract][Full Text] [Related]
31. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
32. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
33. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.
Parmar P; Rao P; Sharma A; Shukla A; Rawal RM; Saraf M; Patel BV; Goswami D
Mol Divers; 2022 Feb; 26(1):389-407. PubMed ID: 34008129
[TBL] [Abstract][Full Text] [Related]
34. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
35. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
Kumar V; Liu H; Wu C
Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
[TBL] [Abstract][Full Text] [Related]
36. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
37. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
38. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
39. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
40. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
Elekofehinti OO; Iwaloye O; Josiah SS; Lawal AO; Akinjiyan MO; Ariyo EO
Mol Divers; 2021 Aug; 25(3):1761-1773. PubMed ID: 33201386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
